Know Labs Stock

Know Labs, Inc. focuses on the development and commercialization of proprietary sensor technologies which, when paired with its artificial intelligence (AI), deep learning platform, are capable of identifying and measuring various materials or analytes using electromagnetic energy to detect, record, identify and measure the unique ‘signature’ of said materials or analytes.

The company calls this its ‘Bio-RFID’ technology platform, when pertaining to radio and microwave spectroscopy, and its ‘ChromaID’ technology platform, when pertaining to optical spectroscopy. The data obtained with its sensor technology is analyzed with its trade secret algorithms, which are driven by its AI deep learning platform.

ChromaID is the first technology developed and patented by the company. The company focuses on extensions and new patentable inventions that are derived from and extend beyond its ChromaID technology and intellectual property. The primary focus of the company is on its Bio-RFID technology and its commercialization and the development of related patent assets. Through its wholly owned subsidiaries, the company works to exploit additional opportunities and markets that its intellectual property and trade secret portfolio addresses.

The Know Labs Technology

The company has internally and under contract with third parties developed proprietary platform technologies to identify and measure almost any organic and inorganic material or analyte. Its patented technology utilizes electromagnetic energy along a range of the electromagnetic spectrum from visible light and infrared to radio and microwave wavelengths to perform analytics, which allow the user to identify and measure materials and analytes depending upon the specified targets or endpoints and field of use. Its proprietary platform technologies are called Bio-RFID and ChromaID.

The company’s technology platform, Bio-RFID, utilizes spectroscopy at higher wavelengths than ChromaID’s optical range to span radio wave and microwave segments of the electromagnetic spectrum. Working in its lab, the company has developed extensions and new inventions derived in part from its ChromaID technology, which it refers to as Bio-RFID. The company is advancing the development of this technology by increasing its accuracy, sensitivity, and specificity. It has announced results confirming that it is able to non-invasively measure blood glucose levels in humans.

The company’s ability to obtain exacting results from the data obtained from its Bio-RFID sensor technology, also referred to as radio frequency spectroscopy or RF spectroscopy, is a consequence of the application of its trade secret algorithms. It will provide the analytics for the list of other analytes in the human body that it will pursue non-invasive detection of, many of which are set forth in its issued patent USPTO 11,033,208 B1. The company’s artificial intelligence (AI) deep learning platform may be separately monetized through its subsidiary, AI Mind, Inc. (AI Mind).

The company continues to build the internal and external development team necessary to commercialize its technology, as well as make additional patent filings covering the intellectual property created with new inventions. The first applications of its Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require the U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market, which it plans to pursue. The company has previously announced two versions of its non-invasive glucose monitoring device. The company has identified these as the KnowU and the UBand. The KnowU will be a desk top version with a portable monitoring device for periodic glucose monitoring and the UBand will be a wearable for continuous glucose monitoring.

The company has also announced the results of internal laboratory-based comparison testing between its Bio-RFID technology and the continuous glucose monitors from Abbott Labs (Freestyle Libre) and DexCom (G6). These results provide evidence of a high degree of correlation between its Bio-RFID technology.

The company has begun the internal process to pursue the U.S. Food and Drug Administration (FDA) approval of its non-invasive blood glucose monitoring device as soon as possible. Additionally, the company has retained third party quality assurance and documentation consultants to ensure that the rigorous requirements of the FDA are met.

The company’s ChromaID patented technology utilizes light at the photon (elementary particle of light) level through a series of emitters and detectors to generate a unique signature or ‘fingerprint’ from a scan of almost any solid, liquid or gaseous material. This signature of reflected or transmitted light is digitized, creating a unique ChromaID signature. Each ChromaID signature includes hundreds to thousands of specific data points.

The ChromaID technology looks beyond visible light frequencies to the areas of near infra-red and ultraviolet light and beyond that are outside the humanly visible light spectrum. The data obtained allows the company to create a very specific and unique ChromaID signature of the substance for a myriad of authentication, verification, and identification applications.

Bio-RFID, ChromaID and AI Deep Learning: Foundational Platform Technologies

The company’s technologies provide a platform upon which a myriad of applications can be developed. As platform technologies, they are analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. Bio-RFID and ChromaID technologies are ‘enabling’ technologies that bring the science of electromagnetic energy to real-world commercialization opportunities across multiple industries.

Utilizing its AI deep learning platform, the company plans to develop analytics which, when using data collected from its sensors, will provide information on health and wellness to end users, and potentially lead to what it calls ‘Predictive Health’. In addition to identifying patterns, the inverse is also possible as its AI deep learning platform can also create patterns in the form of 3D graphical images.

That activity has found its first form in the work of the company’s subsidiary, AI Mind, to generate 3D graphical images, which were sold as non-fungible tokens (NFTs), providing revenue in 2022.

The company is focusing its efforts on productizing its Bio-RFID technology as it moves it out of its research laboratory, through third party validation studies, appropriate and required clinical trials and into the marketplace. At this point in its development cycle the sensor hardware is completed, the product form factor is nearing completion, and the algorithms, which provide results from the data collected by its sensor are in the final development stages.

The company’s subsidiary, Particle, Inc. (Particle), continues to seek a strategic distribution partner or partners to move its virus deactivating light bulb into the global marketplace. Its subsidiary, AI Mind, will, over time, look at additional ways to monetize its AI deep learning platform.

Growth Strategy

The key elements of the company's strategy include entering the diabetes continuous glucose monitoring market with its non-invasive continuous glucose monitoring products; following its entry into the continuous glucose monitoring market, entering other clinical monitoring markets for continuous, non-invasive hormone, medication metabolite, endocrinology components and biomolecular monitoring; and applying its Bio-RFID platform technology to lifestyle analysis, clinical trials and chronic illnesses.

Research and Development

The company incurred expenses of $5,385,586 for the year ended September 30, 2022 on development activities.

Intellectual Property

As of September 30, 2022, the company had been granted 27 patents and 19 design patents. It has a number of patents pending and continues, on a regular basis, with the filing of new patents. The company possesses all rights, title and interest to the issued patents.

The company’s issued patents will expire at various times between 2027 and 2041. The issued patents cover the fundamental aspects of its ChromaID and Bio-RFID technology and a number of unique applications. The company has filed patents on the fundamental aspects of its Bio-RFID technology and growing the number of unique applications.

Government Regulation

The company’s medical diagnostic products and operations, initially the KnowU and UBand glucose monitoring products, are subject to regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FFDCA) and its implementing regulations, guidance documentation, and standards.

History

The company was founded in 1998. It was incorporated under the laws of the state of Nevada in 1998. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in 2018.